GlassScriptPhysician profile
Jeffrey Means
NPI 1518460336
$1,260.99
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $554 · 2023: $388 · 2024: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $239.76 | 2022-2024 | Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $130.62 | 2022-2024 | Iclusig |
| Seagen INC. | $128.98 | 2023 | Tivdak, Adcetris |
| Pharmacosmos Therapeutics INC. | $126.06 | 2022 | |
| Astellas Pharma US INC | $119.16 | 2022-2024 | Xtandi |
| Eisai INC. | $113.76 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $59.96 | 2023-2024 | Tagrisso |
| Merck Sharp & Dohme LLC | $54.20 | 2023-2024 | Keytruda |
| Novartis Pharmaceuticals Corporation | $51.28 | 2024 | |
| Myriad Genetic Laboratories, INC. | $44.73 | 2023 | Precisetumor |
| Daiichi Sankyo INC. | $42.01 | 2022-2023 | Injectafer |
| Pfizer INC. | $37.44 | 2023-2024 | |
| Emd Serono, INC. | $34.20 | 2024 | |
| Tersera Therapeutics LLC | $30.00 | 2023 | Xermelo |
| Regeneron Healthcare Solutions, INC. | $27.61 | 2023 | Libtayo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21.22 | 2023 | Lumakras |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Means listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.